Zinger Key Points
- TOI will pay Kiora an up-front payment of $16 million, and Kiora is eligible to receive milestone payments up to approximately $285 million.
- Kiora Pharmaceuticals also enters into a securities purchase agreement with certain institutional investors.
- Get Monthly Picks of Market's Fastest Movers
Kiora Pharmaceuticals, Inc. KPRX shares are trading higher Thursday after the company announced a private placement of up to $45 million and an exclusive license and development agreement with Théa Open Innovation SAS (TOI).
The Details:
According to an SEC filing, TOI will pay Kiora an up-front payment of $16 million, and Kiora is eligible to receive milestone payments totaling up to approximately $285 million, upon and subject to the achievement of certain specified clinical development, regulatory and commercial milestones.
In addition, Kiora is eligible to receive tiered royalties of between a high single digit to low twenty percent range based on a specified percentage of net sales.
Kiora Pharmaceuticals also entered into a securities purchase agreement with certain institutional investors, pursuant to which Kiora agreed to issue and sell 15,800,000 shares and warrants for expected aggregate gross proceeds at closing of approximately $15 million and potential future warrant exercise gross proceeds of approximately $30 million.
Related News: What’s Going On With Rivian Automotive Stock?
KPRX Stock Prediction 2024:
Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.
Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at Kiora Pharmaceuticals, an investor could make an assessment about a stock's long term prospects using a moving average and trend line. If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For Kiora Pharmaceuticals, the 200-day moving average sits at $0.96, according to Benzinga Pro, which is above the current price of $0.78. For more on charts and trend lines, see a description here.
Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.
KPRX Price Action: According to Benzinga Pro, Kiora Pharmaceutical shares are up 70% at 94 cents at the time of publication.
Image: Leopictures from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.